CN115028735A - Cs1-特异性嵌合抗原受体工程化的免疫效应细胞 - Google Patents

Cs1-特异性嵌合抗原受体工程化的免疫效应细胞 Download PDF

Info

Publication number
CN115028735A
CN115028735A CN202210255676.XA CN202210255676A CN115028735A CN 115028735 A CN115028735 A CN 115028735A CN 202210255676 A CN202210255676 A CN 202210255676A CN 115028735 A CN115028735 A CN 115028735A
Authority
CN
China
Prior art keywords
cells
car
ser
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210255676.XA
Other languages
English (en)
Chinese (zh)
Inventor
余建华
C·霍夫梅斯泰
储剑虹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of CN115028735A publication Critical patent/CN115028735A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
CN202210255676.XA 2013-05-03 2014-05-02 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞 Pending CN115028735A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361819141P 2013-05-03 2013-05-03
US61/819,141 2013-05-03
US201361876492P 2013-09-11 2013-09-11
US61/876,492 2013-09-11
PCT/US2014/036684 WO2014179759A1 (en) 2013-05-03 2014-05-02 Cs1-specific chimeric antigen receptor engineered immune effector cells
CN201480030178.9A CN105377897A (zh) 2013-05-03 2014-05-02 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480030178.9A Division CN105377897A (zh) 2013-05-03 2014-05-02 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞

Publications (1)

Publication Number Publication Date
CN115028735A true CN115028735A (zh) 2022-09-09

Family

ID=51844005

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480030178.9A Pending CN105377897A (zh) 2013-05-03 2014-05-02 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
CN202210255676.XA Pending CN115028735A (zh) 2013-05-03 2014-05-02 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201480030178.9A Pending CN105377897A (zh) 2013-05-03 2014-05-02 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞

Country Status (15)

Country Link
US (3) US10358494B2 (enExample)
EP (2) EP2992020B1 (enExample)
JP (3) JP6856188B2 (enExample)
KR (1) KR102098985B1 (enExample)
CN (2) CN105377897A (enExample)
AU (2) AU2014259675B2 (enExample)
BR (1) BR112015027567B1 (enExample)
DK (1) DK2992020T3 (enExample)
ES (1) ES2777940T3 (enExample)
HU (1) HUE048312T2 (enExample)
IL (1) IL242315B (enExample)
MX (1) MX370173B (enExample)
PL (1) PL2992020T3 (enExample)
PT (1) PT2992020T (enExample)
WO (1) WO2014179759A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2992020B1 (en) * 2013-05-03 2020-01-15 Ohio State Innovation Foundation Cs1-specific chimeric antigen receptor engineered immune effector cells
WO2015120187A1 (en) 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
RU2727451C2 (ru) * 2014-12-05 2020-07-21 Сити Оф Хоуп Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1
HK1245140A1 (zh) * 2014-12-31 2018-08-24 Celgene Corporation 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
JP6912386B2 (ja) * 2015-01-26 2021-08-04 ザ ユニバーシティー オブ シカゴ 癌特異的なＩＬ１３Ｒα２を認識するＣＡＲ Ｔ細胞
CN107683289B (zh) 2015-01-26 2021-08-06 芝加哥大学 IL13Rα2结合剂和其在癌症治疗中的用途
ES3007649T3 (en) * 2015-01-29 2025-03-20 Univ Minnesota Chimeric antigen receptors, compositions, and methods
EP3258967A4 (en) 2015-02-20 2018-10-03 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
WO2016164370A1 (en) * 2015-04-06 2016-10-13 Ohio State Innovation Foundation Egfr-directed car therapy for glioblastoma
EP3298046B1 (en) * 2015-05-20 2025-02-12 Cellectis Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
EP4424326A3 (en) * 2015-06-10 2024-11-13 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
EP3339320A4 (en) 2015-08-17 2019-01-23 Seoul National University R&DB Foundation CHIMERIC ANTIBODY RECEPTOR WITH AN ANTI-COTININ ANTIBODY BELARED AND USE THEREOF
US11517590B2 (en) * 2015-10-08 2022-12-06 National University Corporation Tokai National Higher Education And Research System Method for preparing genetically-modified T cells which express chimeric antigen receptor
TW201740958A (zh) * 2016-01-15 2017-12-01 依圖比克斯公司 用於t細胞免疫療法之方法及組合物
WO2017130223A2 (en) 2016-01-29 2017-08-03 Virocan Therapeutics Pvt. Ltd. A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
US11365237B2 (en) 2016-03-23 2022-06-21 Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Fusion proteins of PD-1 and 4-1BB
EP3445407B1 (en) * 2016-04-22 2022-12-14 CRAGE medical Co., Limited Compositions and methods of cellular immunotherapy
CN109844099B (zh) 2016-07-25 2024-01-02 美国政府(由卫生和人类服务部的部长所代表) 产生经修饰的自然杀伤细胞的方法及使用方法
CN106279432B (zh) * 2016-08-10 2019-09-20 深圳市再生之城生物医药技术有限公司 一种vc-car分子及在清除hiv-1感染细胞中的应用
CN108699163B (zh) * 2016-09-28 2021-11-19 阿思科力(苏州)生物科技有限公司 一种多基因重组嵌合抗原受体分子及其应用
BR112019012950A2 (pt) 2016-12-23 2019-11-26 Macrogenics Inc molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo
JP7033601B2 (ja) * 2017-01-05 2022-03-10 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー 抗コチニンキメラ抗原受容体を発現するナチュラルキラー細胞
US11744862B2 (en) * 2017-03-20 2023-09-05 City Of Hope CS1 targeted chimeric antigen receptor-modified T cells for treatment of AL amyloidosis
AU2018243920B2 (en) * 2017-03-28 2024-12-12 Mayo Foundation For Medical Education And Research Human PD1 peptide vaccines and uses thereof
WO2018189360A1 (en) 2017-04-13 2018-10-18 Cellectis New sequence specific reagents targeting ccr5 in primary hematopoietic cells
EP3648799A4 (en) * 2017-07-07 2021-06-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with mutated cd28 costimulatory domains
US11639508B2 (en) 2017-07-14 2023-05-02 The Johns Hopkins University Engineered TSC2
TWI676483B (zh) * 2017-08-06 2019-11-11 強普生技股份有限公司 醫藥套組及其用途
KR20200063215A (ko) * 2017-10-06 2020-06-04 오슬로 유니버시테시케후스 에이치에프 키메라 항원 수용체
US12077598B2 (en) 2018-03-16 2024-09-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with mutated CD28 phosphorylation sites
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3806871A4 (en) 2018-06-12 2022-02-23 The Regents of the University of California SINGLE-CHAIN BISPECIFIC CHEMICAL ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER
WO2020009868A1 (en) * 2018-07-03 2020-01-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-slamf7 chimeric antigen receptors
EP3818148A4 (en) * 2018-07-05 2022-09-28 Emory University TRANSDUCTION OF CONGENITAL IMMUNE COMPETENT CELLS USING AAV6
WO2020025039A1 (zh) * 2018-08-03 2020-02-06 南京驯鹿医疗技术有限公司 表达嵌合抗原受体的t细胞、该嵌合抗原相关表达载体以及它们的应用
WO2020123716A1 (en) 2018-12-11 2020-06-18 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
CN113966397A (zh) 2019-03-08 2022-01-21 黑曜石疗法公司 人碳酸酐酶2组合物和用于可调调节的方法
IL316764A (en) 2019-04-03 2025-01-01 Prec Biosciences Inc Genetically modified immune cells containing shRNA-targeted microRNA (shRNAmir)
EP3983537A1 (en) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
CA3140668A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
KR20220038362A (ko) 2019-07-02 2022-03-28 프레드 헛친슨 켄서 리서치 센터 재조합 ad35 벡터 및 관련 유전자 요법 개선
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞
AR120430A1 (es) * 2019-11-08 2022-02-16 Humanigen Inc Células car-t dirigidas a epha3 para el tratamiento de tumores
WO2022002919A1 (en) * 2020-06-29 2022-01-06 Julius-Maximilians-Universität Würzburg Slamf7 cars
WO2022031602A1 (en) * 2020-08-06 2022-02-10 Promab Biotechnologies, Inc. Cs1- antibody and anti-cs1-car-t cells
WO2022063302A1 (zh) * 2020-09-25 2022-03-31 克莱格医学有限公司 免疫细胞活性调节
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CN116410331B (zh) * 2021-12-31 2024-01-30 合源生物科技(天津)有限公司 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用
CN120344563A (zh) * 2022-12-02 2025-07-18 广州荔泰生物科技有限公司 人cs1 car-t细胞

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038339A1 (en) * 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
CN1960750A (zh) * 2004-03-29 2007-05-09 Pdl生物制药公司 抗cs1抗体的治疗用途
US20120064083A1 (en) * 2003-05-08 2012-03-15 Abbott Biotherapeutics Corp. Therapeutic use of anti-cs1 antibodies
WO2012071411A2 (en) * 2010-11-22 2012-05-31 Innate Pharma Sa Nk cell modulating treatments and methods for treatment of hematological malignancies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
MX380352B (es) 2006-06-12 2025-03-12 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
EP2626371A1 (en) 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
WO2010017103A2 (en) 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
EP2361263A1 (en) 2008-10-31 2011-08-31 Abbott Biotherapeutics Corp. Use of anti-cs1 antibodies for treatment of rare lymphomas
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2556085A2 (en) 2010-04-05 2013-02-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
ES2754394T3 (es) * 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR101956751B1 (ko) * 2011-10-07 2019-03-11 고쿠리츠다이가쿠호진 미에다이가쿠 키메라 항원 수용체
US20140314667A1 (en) 2011-11-16 2014-10-23 Amgen Inc. Methods of treating epidermal growth factor deletion mutant viii related disorders
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
CN104968788A (zh) 2012-12-07 2015-10-07 索拉兹米公司 包括原始小球藻脂质途径基因的基因工程化微生物菌株
CN103224561A (zh) 2013-01-16 2013-07-31 天津大学 葡萄球菌肠毒素小分子抗体及制备方法及用途
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
EP2992020B1 (en) * 2013-05-03 2020-01-15 Ohio State Innovation Foundation Cs1-specific chimeric antigen receptor engineered immune effector cells
CN105829349B (zh) 2013-10-15 2023-02-03 斯克利普斯研究所 肽嵌合抗原受体t细胞开关和其用途
US20210087275A1 (en) * 2018-03-16 2021-03-25 Cytoimmune Therapeutics, Inc. Bispecific antibody car cell immunotherapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038339A1 (en) * 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US20120064083A1 (en) * 2003-05-08 2012-03-15 Abbott Biotherapeutics Corp. Therapeutic use of anti-cs1 antibodies
CN1960750A (zh) * 2004-03-29 2007-05-09 Pdl生物制药公司 抗cs1抗体的治疗用途
WO2012071411A2 (en) * 2010-11-22 2012-05-31 Innate Pharma Sa Nk cell modulating treatments and methods for treatment of hematological malignancies

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BENSON, D.M.JR等: "CS1-Directed Monoclonal Antibody Therapy for Multiple Myeloma", 《JOURNAL OF CLINICAL ONCOLOGY》, vol. 30, no. 16, 1 June 2012 (2012-06-01), pages 2013, XP055318672, DOI: 10.1200/JCO.2011.40.4061 *
CHU等: "CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma", 《LEUKEMIA》, 15 November 2013 (2013-11-15), pages 917 *
CHU等: "Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells", 《CLIN CANCER RES》, 27 March 2014 (2014-03-27), pages 3989 *
JENA等: "Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor", 《BLOOD》, 19 August 2010 (2010-08-19), pages 1035, XP055021403, DOI: 10.1182/blood-2010-01-043737 *
WR BURNS等: "A high molecular weight-melanoma associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas", 《CANCER RESEARCH》, vol. 70, no. 8, 15 April 2010 (2010-04-15), pages 1 - 2, XP055023662, DOI: 10.1158/0008-5472.CAN-09-2824 *
孙奕 等: "《医学免疫学》", 31 July 2011, 人民军医出版社, pages: 151 - 152 *

Also Published As

Publication number Publication date
JP2016524598A (ja) 2016-08-18
EP3663320A1 (en) 2020-06-10
US20200002418A1 (en) 2020-01-02
JP7221338B2 (ja) 2023-02-13
CN105377897A (zh) 2016-03-02
EP2992020A1 (en) 2016-03-09
WO2014179759A1 (en) 2014-11-06
EP2992020A4 (en) 2016-12-28
DK2992020T3 (da) 2020-02-10
US10358494B2 (en) 2019-07-23
BR112015027567B1 (pt) 2024-02-20
BR112015027567A2 (pt) 2017-12-05
KR102098985B1 (ko) 2020-04-09
AU2019203823A1 (en) 2019-06-20
HK1218925A1 (en) 2017-03-17
US20160075784A1 (en) 2016-03-17
AU2014259675A1 (en) 2015-11-12
JP2019146579A (ja) 2019-09-05
US11845794B2 (en) 2023-12-19
AU2014259675B2 (en) 2019-05-02
JP2021177771A (ja) 2021-11-18
US10227409B2 (en) 2019-03-12
PT2992020T (pt) 2020-02-28
AU2019203823B2 (en) 2021-05-13
MX2015015182A (es) 2016-05-05
PL2992020T3 (pl) 2020-06-01
US20170320941A1 (en) 2017-11-09
ES2777940T3 (es) 2020-08-06
MX370173B (es) 2019-12-04
IL242315B (en) 2020-07-30
JP6856188B2 (ja) 2021-04-07
KR20160003071A (ko) 2016-01-08
HUE048312T2 (hu) 2020-07-28
CA2910666A1 (en) 2014-11-06
EP2992020B1 (en) 2020-01-15

Similar Documents

Publication Publication Date Title
JP7221338B2 (ja) Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞
US20230303653A1 (en) Compositions and methods of chimeric autoantibody receptor t cells
JP7379399B2 (ja) 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
JP2019536452A (ja) 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
CN114615992A (zh) 表达t调节性细胞的抗cd83嵌合抗原受体
CN114929341A (zh) 用于治疗髓系恶性肿瘤的嵌合抗原受体
CA2910666C (en) Cs1-specific chimeric antigen receptor engineered immune effector cells
HK40063360A (en) Compositions and methods of chimeric autoantibody receptor t cells
HK40074993A (en) Compositions and methods of chimeric autoantibody receptor t cells
HK1218925B (en) Cs1-specific chimeric antigen receptor engineered immune effector cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20220909

RJ01 Rejection of invention patent application after publication